Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $1.5 million.

  • Voyager Therapeutics' Non-Current Deffered Revenue fell 8789.6% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 8789.6%. This contributed to the annual value of $6.0 million for FY2024, which is 8144.87% down from last year.
  • Voyager Therapeutics' Non-Current Deffered Revenue amounted to $1.5 million in Q3 2025, which was down 8789.6% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Non-Current Deffered Revenue ranged from a high of $78.9 million in Q1 2023 and a low of $1.5 million during Q3 2025
  • In the last 5 years, Voyager Therapeutics' Non-Current Deffered Revenue had a median value of $12.2 million in 2024 and averaged $20.7 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 83350.69% in 2023, then plummeted by 8789.6% in 2025.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Non-Current Deffered Revenue stood at $8.2 million in 2021, then dropped by 21.44% to $6.4 million in 2022, then skyrocketed by 401.69% to $32.4 million in 2023, then crashed by 81.45% to $6.0 million in 2024, then plummeted by 75.5% to $1.5 million in 2025.
  • Its Non-Current Deffered Revenue was $1.5 million in Q3 2025, compared to $2.6 million in Q2 2025 and $4.8 million in Q1 2025.